The BioIndustry Association has applauded the European Parliament’s decision to appoint the Glenis Willmott, the UK Member of the European Parliament, as the rapporteur on proposals for the new Clinical Trials Regulation.
The proposed Clinical Trials Regulation’s aim is to save time, money and paperwork for companies wishing to run clinical trials across Europe, potentially making it easier to develop medicines for patients, and is something the BIA supports.
Steve Bates, BIA’s chief executive, said: “Glenis understand the concerns of the UK life science sector and has a strong track record of supporting medical research that can lead to life saving treatments. She understands how the existing rules have played a part in the number of clinical trials in Europe falling over recent years.
“So, I am delighted that she will be steering this crucial piece of legislation through the European Parliament.”
